CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...

CRISPR Therapeutics' (NASDAQ: CRSP) stock may be down by 21% this year so far, but that doesn't mean you should write it off ...

Neopyropia is an important economic macroalga and is one of the main macroalgae cultivation species in China, Japan, South ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.

DWJ: I am working with DNA in my PhD as well. More specifically, with CRISPR-based systems for diagnostics purposes. But ...

CREME is a virtual laboratory that allows scientists to simulate specific decreases in gene activity. It offers a powerful new tool for identifying and understanding important parts of the genome. And ...

CRISPR Therapeutics has experienced a 21% decline in its stock value this year. Despite this drop, the biotech company ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara co-present Dr. Jennifer Doudna, CRISPR Gene Editing and the ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

Benjamin Sodey, a former in-house lawyer at life sciences business MilliporeSigma, says he's looking forward to growing his ...